

2cureX participated in the Danish Galathea 3, around the globe, marine expedition.

Copenhagen, Denmark, 25 April 2007: 2cureX participated in the Galathea 3 marine expedition with a project aimed at discovering new fluorescent proteins from remote tropical waters. The project was based on the original discovery of Enhanced Green Fluorescent Protein (EGFP) and associated technologies for using fluorescent proteins in drug discovery. These technologies that have had paramount importance for life science as a whole were invented and patent protected in the mid 1990s by 2cureX founders and colleagues.

The Galathea 3 project was a collaboration between 2cureX and the research group of Professor Peter Roepstorff (University of Southern Denmark).

The Galathea 3 expedition is the third Danish marine expedition going round the globe. The preceding two were in 1847-1849 and 1950-1952. The aim of Galathea 3 was to strengthen Danish research, not only by virtue of the implementation of specific research projects onboard, but also in relation to the international research network of which Denmark is a part. At the same time, Galathea 3 is intended to provide a boost for the recruitment of new scientists in the future (<http://www.galathea3.dk/uk/>).

“The expedition has had all the excitement and adventure that one could hope for. We stayed at a remote island (with no name) north of Gizo (Solomon Islands) with no modern facilities conducting daily dives at night where we identified and collected fluorescent corals. The sample collection was supplemented with diving around St. John and St. Croix (Caribbean). We collected in total more than 120 samples that were analysed in the laboratories on the research vessel, Vædderen” said Ole Thastrup, CEO and Professor, 2cureX.

“We expect that fluorescent proteins with new structural and spectral properties will be identified. Beyond the scientific discovery of novel fluorescent proteins it has been important for 2cureX to show young researchers that a scientific carrier in small biotechnology companies can involve being part of groundbreaking discoveries and adventurous expeditions” continued Ole Thastrup.

Research to fully characterize the collected samples will occur in the laboratories of the University of Southern Denmark and of 2cureX.

Contacts:

Ole Thastrup
Chief Executive Officer

Tel: +45 45822036
e-mail: ot@2curex.com

Timm Jessen
Chief Business Officer

Tel: +49 (4315) 606 448
e-mail: tj@2curex.com

About 2cureX

- 2cureX is a drug discovery company that rapidly generates drug candidates for the treatment of defined populations of cancer patients
- 2cureX is opening the field of drug discovery to hospitals and academic institutions having patient and disease knowledge
- 2cureX's core technology named ChemoCellomics® integrates chemical synthesis of large compound libraries with high throughput cell-based screening (HTS). The proprietary technology allows for the first time high throughput cell-based screening directly in cells from patients. This unique property allows early identification of in-vivo efficacious drug candidates.

About Professor Peter Roepstorff

Peter Roepstorff has with more than 300 scientific papers pioneered the area of protein and peptide structural analysis using mass spectrometry methods. Peter is the recipient of multiple scientific awards honouring his contribution to making mass spectrometry applicable to a wide range of life science areas.